3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
38
Recurrence
6
Neoplasms, Plasma Cell
4
Small Cell Lung Carcinoma
3
Lymphoma
3
Ovarian Neoplasms
2
Disease
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Plasma Cell
1
Leukemia
1
Kidney Neoplasms
1
Immunoglobulin Light-chain Amyloidosis
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Esophageal Neoplasms
1
Amyloidosis
1
Interventions
Dexamethasone
6
Calcium Dobesilate
3
Lenalidomide
2
Cyclophosphamide
2
venetoclax
1
ixazomib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
carfilzomib
1
belantamab mafodotin
1
auricularum
1
Thalidomide
1
Melphalan
1
Lisaftoclax
1
In Situ Hybridization, Fluorescence
1
In Situ Hybridization
1
GTP Cyclohydrolase
1
Drug Evaluation
1
Biological Assay
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Amyloidosis
×
carfilzomib
×
Clear all
NCT02545907
2021-04-15
CATALYST
University College, London
Phase 1/2
Completed
10 enrolled
14 charts